Consider This Before Taking a Position in TECH

Shares of Health Care sector company Bio-Techne moved -1.5% today, and are now trading at a price of $77.63. The Large-Cap stock's daily volume was 897,308 compared to its average volume of 1,099,014. The S&P 500 index returned a -0.0% performance.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company is based in Minneapolis and has 3,200 full time employees. Its market capitalization is $12,233,322,496. Bio-Techne currently offers its equity investors a dividend that yields 0.4% per year.

12 analysts are following Bio-Techne and have set target prices ranging from $65.0 to $95.0 per share. On average, they have given the company a rating of buy. At today's prices, TECH is trading -7.33% away from its average analyst target price of $83.77 per share.

Over the last year, TECH shares have gone down by -1.3%, which represents a difference of -24.5% when compared to the S&P 500. The stock's 52 week high is $89.91 per share and its 52 week low is $51.79. With average free cash flows of $210.58 Million that have been growing at an average rate of 7.2% over the last 5 years, Bio-Techne declining stock performance may not be reflective of the quality of its underlying business.

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2023 254,393 38,244 216,149 -22.9
2022 325,272 44,908 280,364 -8.93
2021 352,164 44,301 307,863 100.6
2020 205,217 51,744 153,473 -1.75
2019 181,619 25,411 156,208 4.53
2018 170,367 20,934 149,433
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.